142 related articles for article (PubMed ID: 18191950)
1. Explicitly accounting for antiretroviral drug uptake in theoretical HIV models predicts long-term failure of protease-only therapy.
Smith RJ
J Theor Biol; 2008 Mar; 251(2):227-37. PubMed ID: 18191950
[TBL] [Abstract][Full Text] [Related]
2. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects.
Smith RJ; Wahl LM
Bull Math Biol; 2004 Sep; 66(5):1259-83. PubMed ID: 15294425
[TBL] [Abstract][Full Text] [Related]
3. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy: where are we?
Hammer SM; Yeni P
AIDS; 1998; 12 Suppl A():S181-8. PubMed ID: 9633001
[No Abstract] [Full Text] [Related]
5. Expanded access programs expanding.
Proj Inf Perspect; 1997 Nov; (23):20-1. PubMed ID: 11365376
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy: coping with failure, planning for success.
Gallant JE
Posit Aware; 1998; 9(3):51-2, 55-7. PubMed ID: 11365489
[TBL] [Abstract][Full Text] [Related]
7. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
8. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads.
Wein LM; D'Amato RM; Perelson AS
J Theor Biol; 1998 May; 192(1):81-98. PubMed ID: 9628841
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral update: recent advances expand options for patients with HIV.
Santhanam H; Goins M
Adv Nurse Pract; 2004 Nov; 12(11):53-4, 56. PubMed ID: 15559568
[No Abstract] [Full Text] [Related]
10. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects.
Smith RJ; Wahl LM
Bull Math Biol; 2005 Jul; 67(4):783-813. PubMed ID: 15893553
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
12. [Salvage therapy for HIV infection].
Salzberger B
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():32-7. PubMed ID: 16385870
[TBL] [Abstract][Full Text] [Related]
13. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
14. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
[TBL] [Abstract][Full Text] [Related]
15. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
16. Global stability of an HIV-1 model with distributed intracellular delays and a combination therapy.
Liu S; Wang L
Math Biosci Eng; 2010 Jul; 7(3):675-85. PubMed ID: 20578792
[TBL] [Abstract][Full Text] [Related]
17. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
18. Therapy of HIV infection.
Chang YC; Tyring SK
Dermatol Ther; 2004; 17(6):449-64. PubMed ID: 15571495
[TBL] [Abstract][Full Text] [Related]
19. Protease inhibitors.
Treat Rev; 1995; (no 19):2. PubMed ID: 11362753
[TBL] [Abstract][Full Text] [Related]
20. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
